Amphastar Pharmaceuticals, Inc. Interest Expense Nonoperating
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-06
- Amphastar Pharmaceuticals, Inc. interest expense nonoperating for the quarter ending 2026-06-30 was $6.66M, a 6.02% increase year-over-year.
- Amphastar Pharmaceuticals, Inc. interest expense nonoperating for the quarter ending 2026-03-31 was $6.55M, a 4.25% increase year-over-year.
- Amphastar Pharmaceuticals, Inc. interest expense nonoperating for the quarter ending 2025-12-31 was $6.63M, a 3.19% increase year-over-year.
- Amphastar Pharmaceuticals, Inc. interest expense nonoperating for the quarter ending 2025-09-30 was $6.28M, a 6.18% decline year-over-year.
- Amphastar Pharmaceuticals, Inc. interest expense nonoperating for fiscal 2025 was $25.48M, a 16.02% decline from fiscal 2024.
- Amphastar Pharmaceuticals, Inc. interest expense nonoperating for fiscal 2024 was $30.34M, a 11.73% increase from fiscal 2023.
- Amphastar Pharmaceuticals, Inc. interest expense nonoperating for fiscal 2023 was $27.16M, a 1371.18% increase from fiscal 2022.
- Amphastar Pharmaceuticals, Inc. interest expense nonoperating for fiscal 2022 was $1.85M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.66M 10-Q · filed 2026-08-06 | $13.21M 10-Q · filed 2026-08-06 | $19.84M derived: sum of 3 quarters · filed 2026-08-06 | $26.13M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $6.55M 10-Q · filed 2026-05-07 | $13.18M derived: sum of 2 quarters · filed 2026-05-07 | $19.47M derived: sum of 3 quarters · filed 2026-05-07 | $25.75M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $6.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $12.91M derived: sum of 2 quarters · filed 2026-02-26 | $19.20M derived: sum of 3 quarters · filed 2026-08-06 | $25.48M 10-K · filed 2026-02-26 |
| 2025-09-30 | $6.28M 10-Q · filed 2025-11-06 | $12.56M derived: sum of 2 quarters · filed 2026-08-06 | $18.85M 10-Q · filed 2025-11-06 | $25.28M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $6.28M 10-Q · filed 2026-08-06 | $12.57M 10-Q · filed 2026-08-06 | $18.99M derived: sum of 3 quarters · filed 2026-08-06 | $25.69M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $6.29M 10-Q · filed 2026-05-07 | $12.71M derived: sum of 2 quarters · filed 2026-05-07 | $19.41M derived: sum of 3 quarters · filed 2026-05-07 | $28.02M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $6.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $13.12M derived: sum of 2 quarters · filed 2026-02-26 | $21.73M derived: sum of 3 quarters · filed 2026-02-26 | $30.34M 10-K · filed 2026-02-26 |
| 2024-09-30 | $6.70M 10-Q · filed 2025-11-06 | $15.31M derived: sum of 2 quarters · filed 2025-11-06 | $23.92M 10-Q · filed 2025-11-06 | $33.37M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $8.61M 10-Q · filed 2025-08-07 | $17.22M 10-Q · filed 2025-08-07 | $26.68M derived: sum of 3 quarters · filed 2026-02-26 | $40.38M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $8.61M 10-Q · filed 2025-05-08 | $18.07M derived: sum of 2 quarters · filed 2026-02-26 | $31.77M derived: sum of 3 quarters · filed 2026-02-26 | $35.37M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $9.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $23.16M derived: sum of 2 quarters · filed 2026-02-26 | $26.76M derived: sum of 3 quarters · filed 2026-02-26 | $27.16M 10-K · filed 2026-02-26 |
| 2023-09-30 | $13.70M 10-Q · filed 2024-11-07 | $17.30M derived: sum of 2 quarters · filed 2024-11-07 | $17.70M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $3.60M 10-Q · filed 2024-08-09 | $4.00M 10-Q · filed 2024-08-09 | ||
| 2022-12-31 | $1.85M 10-K · filed 2025-03-03 |